| Returns | 1W : 11.2% , 1M : 7.7%,1Y : 249.1% |
| Peers & Returns | 1W | 1M | 1Y |
| MARKSANS PHARMA | 11.2% | 7.7% | 249.1% |
| SUN PHARMACEUTICAL INDUSTRIES | 0.6% | -2.5% | 24.9% |
| DRREDDYS LABORATORIES | 3.2% | 19% | 82.6% |
| DIVIS LABORATORIES | 0.9% | -5.9% | 87.6% |
| CIPLA | 5.7% | 5.1% | 69.5% |
| PIRAMAL ENTERPRISES | 5% | -7.8% | -32.6% |
| LUPIN | -1.8% | 7.6% | 37.6% |
| AUROBINDO PHARMA | 7.2% | -2.6% | 28.7% |
| TORRENT PHARMACEUTICALS | 5.7% | 3.5% | 60% |
| Ratio | Value |
|---|---|
|
P/E P/B P/S PEG |
41.09 3.81 4.23 2.77 |
| Model | Discount(-)/ Premium(+) |
|---|---|
|
EV/EBIDTA EV/Sales Price/Sales |
240% 45% 64% |
| Year | Debt/Equity ratio | |
|---|---|---|
|
Debt/Equity ratio analysis
For Banking industry, Good = Ratio less than 13 Average = Ratio between 13 and 15 Bad = Ratio greater than 15 For all non-Banking industries, Good = Ratio less than 0.4 Average = Ratio between 0.4 and 0.6 Bad = Ratio greater than 0.6 Worst is considered between Standalone & Consolidated |
Standalone | Consolidated |
|
2019 2018 2017 Avg_3yrs |
0.16 0.16 0.17 0.16 |
0.18 0.25 0.25 0.23 |
|
[Last Annual Data : Mar2019]
|
||
| Pledged Shares |
0 % |
|---|---|
| As of : July 14,2020 | |
If less than 25% | Good |
| If between 25% and 50% | Neutral |
| If greater than 50% | Bad |
| Parameter | 1 Qtr Growth | 4 Qtr Growth |
|---|---|---|
|
Revenue Op Profit EBIDT Net Income |
37.24% 58.7% 89.23% 197.61% |
68.75% 133.71% 215.1% 290.03% |
| QtrlyTrend |
8
Quarterly Trend analysis
The growth rate score are assigned as under: If ratio's 1Q growth is +ve, then 1. If -ve, then -1. If ratio's 4Q growth is +ve, then 1.If -ve, then -1. Growth Score= Sum of all the above scores for Revenue, Operating Profit and Net Income. Interpretation Good = Growth Score >=4 Neutral = Growth Score between 0 and 4 Bad = Growth Score less than 0 |
|
| Latest Qtr: Jun2020 | ||
